Vigil Neuroscience

Sanofi to Acquire Vigil Neuroscience for Up to $600 Million, Expanding Alzheimer's Disease Pipeline

2 days ago

• Sanofi has entered into a definitive merger agreement to acquire Vigil Neuroscience for $8.00 per share in cash upfront, with an additional $2.00 per share contingent value right tied to VG-3927's first commercial sale. • The acquisition strengthens Sanofi's neurology pipeline with VG-3927, a Phase 2-ready oral small molecule TREM2 agonist being developed for Alzheimer's disease, targeting microglial dysfunction in neurodegenerative disorders. • The transaction, valued at approximately $600 million including the potential CVR payment, is expected to close in the third quarter of 2025, with Vigil's monoclonal antibody program iluzanebart not included in the acquisition.

Vigil Neuroscience's VG-3927 Shows Promise in Phase 1 Alzheimer's Trial, Advancing to Phase 2

4 months ago

• Vigil Neuroscience reports positive Phase 1 data for VG-3927, an oral TREM2 agonist, showing a favorable safety profile in healthy adults and Alzheimer's patients. • The trial demonstrated robust, dose-dependent reductions in sTREM2 levels in cerebrospinal fluid, indicating strong target engagement and potential neuroprotective effects. • Vigil plans to advance VG-3927 into a Phase 2 clinical trial in Q3 2025, using a 25mg once-daily oral dose based on Phase 1 findings. • VG-3927's unique mechanism aims to enhance microglial function without increasing inflammation, offering a differentiated approach to Alzheimer's treatment.

Immunic's Vidofludimus Calcium Shows Promise in Multiple Sclerosis Trials

5 months ago

• Immunic's phase 2 CALLIPER trial of Vidofludimus Calcium in progressive multiple sclerosis is expected to report top-line data in April. • Interim analysis of the phase 3 ENSURE trials for relapsing multiple sclerosis showed positive outcomes, with completion expected in 2026. • Vidofludimus Calcium targets Nurr1 activation for neuroprotection and DHODH inhibition for anti-inflammatory and antiviral effects in MS.